National HealthCare Corporation (NHC) is rated a Buy due to its attractive valuation at a 13% EV/EBITDA discount compared to peers, despite superior EBITDA margins and strong operating leverage. The company benefits from rising occupancy rates, higher reimbursement rates, and a recent $560 million real estate acquisition that enhances operational control and cash flow. Supported by favorable U.S. demographic trends and industry supply constraints, NHC is positioned for continued earnings growth and pricing power. The company maintains a conservative balance sheet, robust cash flows, and a growing dividend, with potential for further earnings and dividend increases.
National HealthCare Corporation's valuation is noted for a 13% EV/EBITDA discount versus peers, highlighting its strong operating leverage and business improvements. For readers following the health sector, here is Pluang's market snapshot as of Oct 06, 2026 18:43 WIB: out of 100 priced US health stocks, 68 rose and 24 fell today. Notable movers include Twist Bioscience Corp (TWST) at USD 210.32 with a 1-day change of +2.60% and a typical hold time on Pluang of 27 days, Crispr Therapeutics AG (CRSP) at USD 58.81 with a +2.56% change and 77 days hold time, and Amylx Pharmaceuticals Inc (AMLX) at USD 28.49 with a +2.56% change and 15 days hold time.
Morgan Stanley analyst Bob Huang lowered American International Group's (AIG) price target to $80 from $81, with the stock trading around $76, indicating potential upside. AIG is set to report its Q3 2026 earnings on November 3, with investors focuse...
Vertiv Holdings, a maker of power and cooling equipment for data centers, faces mixed analyst opinions with GLJ Research rating it a "Sell" and BMO Capital giving an "Outperform" rating. Despite a recent stock pullback, the company reported a 241% in...
Apogee Enterprises reported strong fiscal Q2 results with adjusted earnings of $1.17 per share, nearly double the estimated $0.59, and revenue of $391.14 million, surpassing expectations of $362.6 million. This marks a continued trend of beating esti...
McKesson received a bullish price target of $977 from Morgan Stanley, suggesting a 6.7% upside from its current price of $915.45. The company agreed to acquire Option Care Health for $32.05 per share, valuing the deal at approximately $5.8 billion in...
Ameriprise Financial has authorized an additional $5.5 billion for share repurchases through September 2028, supported by $2.1 billion in excess capital and $2.8 billion in liquidity. The company returned $1.9 billion to shareholders in H1 2026, incl...
